Navigation Links
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Date:1/12/2009

Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's expectation regarding the timing of reporting results of the validation study, the company's belief that the initiation of the clinical validation study brings it closer to delivering a tool that may lead to more targeted approaches to treating stage II colon cancer, and the potential utility, attributes or impact of a predictive or prognostic test for stage II colon cancer. These risks and uncertainties include, but are not limited to: the results of the clinical validation study; delays or difficulties in completion of the clinical validation study; the applicability of clinical study res
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
5. Transgenomic Receives Accreditation From College of American Pathologists
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
8. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
9. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
10. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
11. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...PRNewswire/ -- DSM Pharmaceutical Products today a... with Galenix, Saint Jean D,Illac, France, where D...uring partner for Galenix commercial products on a...ate on business development opportunities co-marke...the strength of Galenix in drug product developmen...
(Date:11/5/2009)...Newswire-FirstCall/ -- BioSpecifics Technologies C... developing first-in-class collagenase-based produ... third quarter ended September 30, 2009. ,, "W...year, the FDA,s Arthritis Advisory Committee unani...l of XIAFLEX(TM) for the treatment of Dupuytren,s ...
(Date:11/5/2009)...ewswire/ -- SpineSmith Partners has signed an init...unique scaffold that mimics the structure of natur...al commercial products by SpineSmith,s Research an... GenOsteo scaffold represents a significant advanc...l environment for the delivery of adult stem cells...
(Date:11/4/2009)...ebinar, which will be presented on November 19 and...ow chemistry processing, will deal with the applic...s meso and micro scale flow chemistry equipment. ...been recognized with several prestigious prizes an...dron Prize. , Columbia, M...
Breaking Biology Technology:DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3
...ation,(Nasdaq: CRGN ), a clinical-stage biopharma...ced that it received a letter, dated January 28,20...n that during the,preceding 30 consecutive trading...tock has been below the $1.00 minimum bid per shar...bal Market under NASDAQ Marketplace Rule,4450(a)(5...
...cientific Inc. (NYSE: TMO ), the world leader in ... the 2008 Merrill Lynch Global Pharmaceutical,Biot...t the Grand Hyatt,Hotel in New York City. The comp...9:20 am (EST)., Marijn E. Dekkers, president and ...c, will provide an overview of the company and dis...
...iences, Inc. (Nasdaq: SGMO ) today announced that...ear-end 2007 financial results on Tuesday,February...se will be,followed by a conference call at 2:00 p...hone and webcast. During the conference call, the ...uss other business matters., The conference call ...
Other Biology Technology:CuraGen Corporation Receives Notification from NASDAQ 2CuraGen Corporation Receives Notification from NASDAQ 3Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast 3
(Date:11/4/2009)...-FirstCall/ -- BIO-key International, Inc. (OTC Bu...etric identification software is showcasing donor ...nference being held at the New Orleans Convention ...de hands-on product demonstrations of its state-of...Also, at 5 PM on Monday, October 26, Peter Lux, ma...
(Date:11/4/2009)... Glencoe Software, Inc., the commercial arm of the...ttp://openmicroscopy.org ), is proud to announce ...l Biology,s exciting new project titled "The Cell:....5M stimulus grant through the National Institutes... part of the American Reinvestment and Recovery Ac...
(Date:11/3/2009)...rt published in a recent issue of HortTechnology ...ed the effects of covering orchard floors with ref...y light distribution, orchard temperature, and pro...xtenday and Solarmate films installed 5 weeks befo..., apples. The research showed that the use of both...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Reflective film can boost profits for apple growers 2Cepheid Reports 2009 Second Quarter Results 53277 1Cepheid Reports 2009 Second Quarter Results 53277 2Cepheid Reports 2009 Second Quarter Results 53277 3Cepheid Reports 2009 Second Quarter Results 53277 4Cepheid Reports 2009 Second Quarter Results 53277 5Cepheid Reports 2009 Second Quarter Results 53277 6Cepheid Reports 2009 Second Quarter Results 53277 7Cepheid Reports 2009 Second Quarter Results 53277 8Cepheid Reports 2009 Second Quarter Results 53277 9Cepheid Reports 2009 Second Quarter Results 53277 10Cepheid Reports 2009 Second Quarter Results 53277 11Cepheid Reports 2009 Second Quarter Results 53277 12Cepheid Reports 2009 Second Quarter Results 53277 13Cepheid Reports 2009 Second Quarter Results 53277 14Cepheid Reports 2009 Second Quarter Results 53277 15Cepheid Reports 2009 Second Quarter Results 53277 16Cepheid Reports 2009 Second Quarter Results 53277 17Cepheid Reports 2009 Second Quarter Results 53277 18Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 13296 1Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 13296 2Flu Shot May Be Less Effective in Those With Lupus 53274 1Flu Shot May Be Less Effective in Those With Lupus 53274 2
...lease is also available in Spanish . , Barcelo... number of times women undergo assisted reproducti...the overwhelming majority achieve a pregnancy with...age of 40 had a more consistent, but lower, pregna...attempts. , Mr Simon Hong told the 24th annual m...
...e current drive towards production of alternative ... down this material into useable compounds are req... One group of scientists from Texas A&M University...e the enzymes. Professor Zivko Nikolov, who leads...rch on Monday 7th July at the Society for Experime...
...STATION, July 7, 2008 A study published in the cu...belief that diversity of marine species has been i.... Dr. Thomas D. Olszewski, a geology and geophysic...rt of the international team that carried out this...he diversification occurred early on relatively s...
Other Biology News:Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle 2Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle 3A green solution to biofuel production 2Setting the record right: species diversity less dramatic than previously believed 2
The Protein Kinase Factsbooks (2 Volume Set) from Promega
...ning Kit, 1. Select from homogeneous and gradient ... on denaturing, native, and isoelectric focusing g...cast gels, buffer strips, and staining kits.Achiev...oisotopes with ready-to-use silver staining kits. ...
Mouse Anti-STAPHYLOCOCCUS ENTEROTOXIN B (+C2, +D) Monoclonal Antibody, Unconjugated, Clone S5 from AbD Serotec
Porcine Serum from Lifeblood Medical, Inc.
Biology Products: